Apurva C.

Apurva C. has a wealth of experience in the field of toxicology and pharmacology. Apurva began their career in 2006 as a Research Scientist - Pharmacology at CymaBay Therapeutics, where they designed, executed, and interpreted pharmacology studies including histology, assay development, and in vivo studies for target validation for small molecule diabetes drugs. In 2015, they moved to Boehringer Ingelheim and Dynavax Technologies Corp as a Bioanalytical Researcher. Two years later, they became the Head of In vivo Pharmacology at Applied Molecular Transport. Currently, Apurva C. is the Head of Toxicology and Pharmacology at TrueBinding.

Apurva C. is currently pursuing a Doctor of Philosophy (Ph.D.) in Neurobiology at Mohanlal Sukhadia University. Additionally, they have obtained a Good Clinical Practice (GCP) certification from the NIDA Clinical Trials Network in January 2023.